Focus: Aspen Surgical is a specialty pharmaceutical company headquartered in Michigan focused on women's health and surgical equipment with a highly concentrated revenue model. The company operates as a niche player in biotechnology with legacy hormone-based therapies.
Profile data last refreshed 29m ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Aspen Surgical to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Aspen Surgical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core revenue driver (100% of portfolio) but in pre-launch stage with minimal Part D spending, indicating market uptake challenges or early commercialization phase.
Help build intelligence for Aspen Surgical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Legacy anticoagulant product facing patent expiration with no differentiation strategy evident; revenue data unavailable.
Established women's health asset approaching loss of exclusivity with well-characterized pharmacology but limited commercial visibility.
Generic corticosteroid in LOE_APPROACHING stage with no differentiation; revenue minimal or zero.
Generic hydroxyprogesterone caproate (ANDA) in post-LOE stage; duplication of brand product indicates market erosion from generics.
Specialty formulation of heparin sodium facing patent expiration; minimal revenue visibility.
Preservative-free heparin variant in LOE_APPROACHING stage; formulation differentiation insufficient to protect against generic erosion.
Synthetic conjugated estrogen product facing patent cliff with established women's health indication but no competitive advantage evident.
Injectable dexamethasone phosphate formulation in LOE_APPROACHING stage; generic competition and patent expiration imminent.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo